Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways-Reference-Cited by-同舟云学术

Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways

Published:2018-06-26 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Jiang Wenjing,Li Guangxin,Li Weidong,Wang Ping,Xiu Peng,Jiang Xian,Liu Bing,Sun Xueying^ORCID,Jiang Hongchi

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-28010-y.pdf

Reference42 articles.

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA: a cancer journal for clinicians 67, 7–30, https://doi.org/10.3322/caac.21387 (2017).

2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359, 378–390 (2008).

3. Cheng, A.-L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology 10, 25–34 (2009).

4. Waidmann, O. & Trojan, J. Novel drugs in clinical development for hepatocellular carcinoma. Expert opinion on investigational drugs 24, 1075–1082, https://doi.org/10.1517/13543784.2015.1058776 (2015).

5. Berasain, C. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? Gut 62, 1674–1675, https://doi.org/10.1136/gutjnl-2013-304564 (2013).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potassium channels as novel molecular targets in hepatocellular carcinoma (Review);Oncology Reports;2023-08-24

2. Coleon U, Isolated from Plectranthus mutabilis Codd., Decreases P-Glycoprotein Activity Due to Mitochondrial Inhibition;Pharmaceutics;2023-07-12

3. V₄C₃ MXene Immune Profiling and Modulation of T Cell‐Dendritic Cell Function and Interaction;Small Methods;2023-06-08

4. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights;Frontiers in Pharmacology;2022-08-22

5. Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis;Frontiers in Pharmacology;2022-08-22